Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Hidetoshi Sumimoto"'
Autor:
Hidetoshi Sumimoto, Satoshi Noda, Hiroyoshi Koide, Yutaro Douke, Kosuke Sakai, Akihito Nishikawa, Azumi Tomioka, Maki Hori, Hiromi Nakato, Yuri Kimura, Aya Tokuda, Atsushi Takano, Koji Teramoto, Satoshi Murata, Yataro Daigo
Publikováno v:
PLoS ONE, Vol 19, Iss 7, p e0306995 (2024)
Immune checkpoint inhibitors (ICIs) have been widely used as standard therapies for various cancers. However, in 20-30% of cases, ICIs can lead to immune-related adverse events (irAEs), which sometimes require discontinuation of treatment. Due to the
Externí odkaz:
https://doaj.org/article/bc0fbd3f6a2940db8789afc28ca8bcbb
Autor:
Hidetoshi Sumimoto, Atsushi Takano, Tomoyuki Igarashi, Jun Hanaoka, Koji Teramoto, Yataro Daigo
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Epidermal growth factor receptor (EGFR)-mutated (mt) lung adenocarcinoma (LA) is refractory to immune checkpoint inhibitors (ICIs). However, the mechanisms have not been fully elucidated. CD8+ T cell infiltration was significantly lower in E
Externí odkaz:
https://doaj.org/article/df05e612951a40819d98461eba755d42
Autor:
Hidetoshi Sumimoto, Komaki Hayashi, Yuri Kimura, Akihito Nishikawa, Seiko Hattori, Chiaki Hasegawa, Hiroaki Morii, Koji Teramoto, Sachiyo Morita, Yataro Daigo
Publikováno v:
Palliative Medicine Reports, Vol 2, Iss 1, Pp 237-241 (2021)
Background: There are no universal tools to predict the necessity of high-dose opioid use for cancer-related pain. Early recognition and interventions for intractable cancer pain could minimize the distress of palliative patients. Objective: We sough
Externí odkaz:
https://doaj.org/article/4f36d8ea98cc44368c5397637a853499
Publikováno v:
PLoS ONE, Vol 11, Iss 11, p e0166626 (2016)
Ectopic programmed cell death ligand 1 (PD-L1) expression in non-small cell lung cancers (NSCLCs) is related to immune evasion by cancer, and it is a molecular target of immune checkpoint therapies. Although some altered signals in NSCLCs are respons
Externí odkaz:
https://doaj.org/article/5b671c79f41b4b1ab60428088b67c3e5
Autor:
Yuri Kimura, K. Hayashi, Yataro Daigo, Hiroaki Morii, Chiaki Hasegawa, Akihito Nishikawa, Hidetoshi Sumimoto, Seiko Hattori, Sachiyo Morita, Koji Teramoto
Publikováno v:
Palliative Medicine Reports
Background:There are no universal tools to predict the necessity of high-dose opioid use for cancer-related pain. Early recognition and interventions for intractable cancer pain could minimize the distress of palliative patients.
Objective:We so
Objective:We so
Autor:
Jun Hanaoka, Koji Teramoto, Yoko Kataoka, Mitsuaki Ishida, Yataro Daigo, Hidetoshi Sumimoto, Tomoyuki Igarashi
Publikováno v:
Cancer Immunology, Immunotherapy. 70:1063-1074
Programmed cell death-ligand 1 (PD-L1) expression on tumor cells is induced by interferon-gamma, suggesting the induction of an anti-tumor immune response. In turn, binding of PD-L1 to programmed cell death 1 (PD-1) triggers an immune checkpoint path
Autor:
Kazuya Teramura, Hiroaki Morii, Hidetoshi Sumimoto, Seiko Hattori, Koji Teramoto, Yataro Daigo, Yuri Kimura, Sachiyo Morita, K. Hayashi, Chiaki Hasegawa
Publikováno v:
Palliative Care Research. 15:161-166
Autor:
Koji, Teramoto, Tomoyuki, Igarashi, Yoko, Kataoka, Mitsuaki, Ishida, Jun, Hanaoka, Hidetoshi, Sumimoto, Yataro, Daigo
Publikováno v:
Cancer immunology, immunotherapy : CII. 70(4)
Programmed cell death-ligand 1 (PD-L1) expression on tumor cells is induced by interferon-gamma, suggesting the induction of an anti-tumor immune response. In turn, binding of PD-L1 to programmed cell death 1 (PD-1) triggers an immune checkpoint path
Autor:
Yataro Daigo, Hidetoshi Sumimoto, Jun Hanaoka, Koji Teramoto, Tomoyuki Igarashi, Mitsuaki Ishida, Yoko Kataoka
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 137
Objectives Cancer-associated fibroblasts (CAFs) are a dominant cell type in tumor stroma and support the generation of pro-tumorigenic microenvironment. CAFs have frequent opportunities to interact with immune cells infiltrating the tumor stroma, but
Publikováno v:
Cancer Research. 80:1019-1019
EGFR mutation-positive (EGFRmt) lung adenocarcinoma (LA) is refractory to immune checkpoint inhibitors, such as anti-PD-1/anti-PD-L1 mAbs. However, the refractory mechanism remains to be elucidated. We found CD8A mRNA level was significantly lower in